Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566).

Detaljer

Författare
  • Marie-Cécile Le Deley
  • Michael Paulussen
  • Ian Lewis
  • Bernadette Brennan
  • Andreas Ranft
  • Jeremy Whelan
  • Gwénaël Le Teuff
  • Jean Michon
  • Ruth Ladenstein
  • Perrine Marec-Bérard
  • Henk van den Berg
  • Lars Hjorth
  • Keith Wheatley
  • Ian Judson
  • Heribert Juergens
  • Alan Craft
  • Odile Oberlin
  • Uta Dirksen
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Sidor (från-till)2440-2448
TidskriftJournal of Clinical Oncology
Volym32
Utgivningsnummer23
StatusPublished - 2014
PublikationskategoriForskning
Peer review utfördJa